Fulgent Genetics (FLGT) Q2 FY26 earnings call

Fulgent Genetics reported Q2 FY26 results marked by significant challenges in its revenue cycle management system, leading to lower collection rates and a downward revision of full-year revenue and EPS guidance. Despite these operational headwinds, the company's therapeutic development pipeline showed promising progress, with FID-07 advancing towards Phase 3 and FID-022 completing its fourth dose level in Phase 1. Acquisitions of Bako and StrataDX contributed to strong growth in Anatomic Pathology, though their integration coincided with the RCM issues.